Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 29 of 36 / 848 articles
Two years after nicotine pouches went mainstream, the data is beginning to clarify the public health impact. The results so far: mostly positive, with important caveats that demand regulatory attention.
A smoker whose partner quits is far more likely to quit themselves. A smoker whose partner smokes faces dramatically higher odds of relapse. The social network is as powerful as any pharmacological intervention.
Australia pioneered plain packaging in 2012, facing down industry lawsuits and trade challenges. A decade later, over 20 countries have followed. The evidence is in: plain packaging works—and the industry's predictions of disaster were wrong.
In 2019, the U.S. raised the federal minimum age for tobacco sales to 21. Five years of data later, the results are in, and they're both encouraging and complicated.
Nicotine has measurable pain-relieving effects, which helps explain why smoking rates are elevated among chronic pain patients. Understanding this connection is essential for addressing one of the most refractory smoking populations.
A second journey through the nicotine landscape confirms the patterns from the first: complexity resists simplification, institutions lag behind evidence, and the human dimension of addiction demands compassion.
Your spouse, parent, or adult child has switched from smoking to vaping. You're worried, confused, and not sure what to say. Here's what the evidence says about supporting—not sabotaging—their transition.
Across Latin America, the tobacco industry has perfected a set of strategies to delay, weaken, and defeat tobacco control legislation. The playbook is consistent across countries—and it's devastatingly effective.
Five years ago, the evidence on passive vaping was thin and contested. Since then, a substantial body of research has emerged—and it's changing how policymakers and venue operators think about indoor vaping.
For decades, researchers have pursued a vaccine that would block nicotine from reaching the brain, making smoking unrewarding and quitting effortless. The science is tantalizing. The clinical trials have all failed. What's next?
While the Western policy debate focuses on vaping and pouches, roughly 100 million people—mostly in South Asia—smoke bidis: cheap, hand-rolled cigarettes that are even more toxic than conventional cigarettes and almost entirely unregulated.
There are hundreds of smoking cessation apps. Most have never been tested. A handful have evidence of effectiveness. The gap between the app stores and the evidence base is a public health opportunity—and a consumer protection problem.
Nicotine is a stimulant that disrupts sleep architecture—but smokers use it to manage the fatigue that poor sleep causes. The nicotine-sleep cycle is a trap that's rarely discussed in cessation counseling, and it should be.
Helping tobacco farmers switch to alternative crops is essential to tobacco control—and extraordinarily difficult to do well. The history of transition programs is a study in good intentions, structural barriers, and the rare successes.
Schools spent millions on bathroom sensors to catch students vaping. But students adapted faster than the technology, and the backlash—from parents, civil liberties groups, and students themselves—is growing.
Every two years, delegates from over 180 countries gather to shape global tobacco policy. The COP is where the FCTC's future is decided—amid industry lobbying, harm-reduction disputes, and the grinding reality of international diplomacy.
A cigarette is the end product of a global supply chain that spans continents, employs millions, and generates billions in profit. Understanding that chain reveals where the power lies—and where interventions could be most effective.
Quitting smoking isn't just about breaking a chemical addiction. It's about reconstructing a sense of self that was built around cigarettes. The psychology of ex-smoker identity is one of the most neglected dimensions of cessation.
Nicotine enhances neuroplasticity—the brain's ability to reorganize and form new connections. That's why it improves cognition in the short term and why addiction is so persistent. Understanding the mechanism is key to better treatments.
Early biomarker research suggests that switching from smoking to vaping reverses some—but not all—of the immune dysregulation caused by cigarettes. The implications for respiratory health, autoimmune disease, and cancer surveillance are profound.
Every year that evidence-based harm reduction is delayed, millions of smokers who might have switched to safer products continue to smoke—and die. What does the economic modeling tell us about the cost of precautionary paralysis?
Over 90% of the world's vaping hardware comes from a single district in Shenzhen, China. The concentration of manufacturing in one place has profound implications for innovation, regulation, and the future of nicotine consumption worldwide.
The average successful ex-smoker tried and failed 5–7 times before quitting for good. Those 'failures' weren't wasted effort—they were essential practice. Understanding the quit cycle transforms how we think about cessation.
Financial technology has 'regulatory sandboxes' where startups can test innovations under supervision. Could the same model work for nicotine products—allowing harm-reduction innovation while maintaining safety oversight?
Products
Select a product to view details, highlights, and technical specifications.
